Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Anti-obesity drug Mounjaro is set rack up sales of nearly £22bn a year by 2030. But Trump's 'America First' policies mean Britons could soon be paying more for the 'King Kong' of weight-loss jabs ...

Zepbound, which was only introduced in November ... A combination of factors including cost, availability, and competition are weighing on Eli Lilly’s sales growth Part of the problem both ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

"Offering Zepbound single-dose vials […] through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved, and regulated obesity treatment ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co ... beating Novo Nordisk in large part thanks to the availability of supply. Nonetheless, shares of Eli ...

Ivim Health raises concern over US FDA’s arbitrary critical deadline comes; submits Amicus brief to fighting patient access to GLP-1 medications: Columbus, Ohio Thursday, Februa ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...